Literature DB >> 23107976

The effect of intraarterial high-dose cisplatin on lymph nodes in oral and oropharyngeal cancer.

A F Kovács, N Döbert, K Engels.   

Abstract

AIM OF STUDY: To assess the effect of strictly local treatment [intraarterial chemotherapy (iaCHT) with high-dose cisplatin and parallel neutralization] in the primary oral and oropharyngeal cancer (OOSCC) on the dependent cervical lymph nodes. PATIENTS AND METHODS: Seventeen consecutive patients with OOSCC and clinically positive necks underwent a prospective blinded comparison of two pre-surgical fluor18-deoxyglucose (FDG)-positron emission tomography (PET) examinations: baseline examination 1 week before and follow-up examination 3 weeks after iaCHT. Maximal standardized uptake (SUVmax) values of lymph nodes were measured and compared with each other and histopathology.
RESULTS: The SUVmax value of the primary and all neck lymph nodes with uptake decreased significantly. Twelve/17 patients having metastases revealed significant decrease (P = 0.03), and benign lymph nodes showed non-significant decrease of the SUVmax. All neck lymph nodes with uptake and nodal metastases showed a significant reduction (P = 0.004) of standard uptake values (SUV).
CONCLUSION: A regional effect of intraarterial cisplatin is proven. To date, it is not clear whether this is due to decreasing inflammatory reaction or a translymphatic anti-neoplastic effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107976     DOI: 10.4103/0019-509X.102918

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  1 in total

1.  Analytical Study on the Efficacy of Neoadjuvant Chemotherapy Using a Combination of Methotrexate, Bleomycin, and Cisplatin in the Management of Advanced Squamous Cell Carcinoma of the Buccal Mucosa.

Authors:  Santosh Manohar Kumar; Srabani Biswas; Shreya Sarkar; Syam Sundar Mandal; Jaydip Biswas
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jul-Sep
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.